HC Wainwright Lowers KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective lowered by HC Wainwright from $24.00 to $20.00 in a research note released on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the specialty pharmaceutical company’s stock.

Separately, Needham & Company LLC reaffirmed a buy rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, May 1st.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $12.14 on Friday. KalVista Pharmaceuticals has a 52 week low of $7.21 and a 52 week high of $16.88. The company has a market cap of $512.19 million, a PE ratio of -3.85 and a beta of 0.92. The firm has a 50 day simple moving average of $12.09 and a 200 day simple moving average of $11.45.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). On average, equities analysts predict that KalVista Pharmaceuticals will post -3.05 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Edward P. Feener sold 28,288 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $14.07, for a total value of $398,012.16. Following the completion of the sale, the insider now owns 62,157 shares of the company’s stock, valued at approximately $874,548.99. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Thomas Andrew Crockett sold 24,888 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $14.11, for a total value of $351,169.68. Following the completion of the sale, the chief executive officer now owns 211,203 shares of the company’s stock, valued at approximately $2,980,074.33. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Edward P. Feener sold 28,288 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $14.07, for a total transaction of $398,012.16. Following the transaction, the insider now directly owns 62,157 shares in the company, valued at $874,548.99. The disclosure for this sale can be found here. Insiders have sold a total of 75,978 shares of company stock valued at $1,070,918 in the last three months. Insiders own 12.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its stake in shares of KalVista Pharmaceuticals by 1.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 84,309 shares of the specialty pharmaceutical company’s stock valued at $812,000 after acquiring an additional 1,508 shares in the last quarter. Strs Ohio bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth $104,000. Principal Financial Group Inc. acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $109,000. New York State Common Retirement Fund raised its holdings in KalVista Pharmaceuticals by 1,860.4% in the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 9,451 shares during the period. Finally, Quantbot Technologies LP acquired a new position in KalVista Pharmaceuticals during the 3rd quarter worth $31,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.